Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ICMT | O60725 | 2/20 | 0.37 |
| ▸ | CAPN1 | P07384 | 2/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.33 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.33 |
| ▸ | UTS2R | Q9UKP6 | 1/20 | 0.33 |
| ▸ | HPGD | P15428 | 2/20 | 0.32 |
| ▸ | HTT | P42858 | 1/20 | 0.32 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.32 |
| ▸ | JAK3 | P52333 | 1/20 | 0.31 |
| ▸ | BTK | Q06187 | 1/20 | 0.31 |
| ▸ | MEN1 | O00255 | 1/20 | 0.31 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.31 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.31 |
| ▸ | TSHR | P16473 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22800074 | 0.82 | ICMT (0.35) | ICMTCAPN1KDM4EUTS2RHTT | |
| SCHEMBL22800782 | 0.81 | ICMT (0.37) | ICMTCAPN1ALDH1A1KDM4EHPGD | |
| SCHEMBL22800781 | 0.76 | CAPN1 (0.35) | ICMTCAPN1ALDH1A1KDM4EHPGD | |
| SCHEMBL22800194 | 0.73 | CAPN1 (0.47) | ICMTCAPN1KDM4EHPGDMEN1 | |
| SCHEMBL22800072 | 0.71 | CAPN1 (0.34) | ICMTCAPN1KDM4EHTTTDP1 | |
| SCHEMBL22799765 | 0.69 | MAPT (0.35) | ALDH1A1UTS2RTDP1JAK3BTK | |
| SCHEMBL22799633 | 0.69 | LIG1 (0.44) | ALDH1A1KDM4EHPGDTDP1MEN1 | |
| SCHEMBL22800170 | 0.68 | KDM4E (0.43) | ALDH1A1KDM4EHPGDMEN1KMT2A | |
| SCHEMBL22800154 | 0.68 | ALDH1A1 (0.46) | ALDH1A1KDM4EMEN1KMT2ATSHR | |
| SCHEMBL22800135 | 0.65 | CAPN1 (0.49) | ICMTCAPN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20200392157-A1 | CALPAIN MODULATORS AND THERAPEUTIC USES THEREOF | Knobbe, Martens, Olson & Bear, LLP | 2020-12-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200392157-A1 | CALPAIN MODULATORS AND THERAPEUTIC USES THEREOF | CAPNS1, CAPN2, CAPN1 | ICMT 4672/4885CAPN1 3/4885ALDH1A1 3918/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.